The advent of genome editing has transformed the therapeutic landscape for several
debilitating diseases, and the clinical outlook for gene therapeutics has never been more …

The oligonucleotide therapeutics field has seen remarkable progress over the last few years
with the approval of the first antisense drug and with promising developments in late stage …

Polyethlyenimine (PEI) was introduced 1995 as a cationic polymer for nucleic acid delivery.
PEI and its derivatives are extensively used in basic research and as reference formulations …

Antisense miRNA oligonucleotides against miR-21 (AMO-21) have a therapeutic potential
for treatment of glioblastoma. However, glioblastoma-targeted delivery through systemic …

CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …

Brain delivery is one of the major challenges in drug development because of the high
number of patients suffering from neural diseases and the low efficiency of the treatments …

Despite the recent progress in cancer management approaches, the mortality rate of cancer
is still growing and there are lots of challenges in the clinics in terms of novel therapeutics …

MicroRNAs (miRNAs) are non-coding endogenous RNAs that direct post-transcriptional
regulation of gene expression by several mechanisms. Activity is primarily through binding …

Antimicrobial resistant (AMR) infections are a growing threat to public health and there is a
general lack of development in new antibiotics. Here, a dextran‐coated stimuli‐responsive …

The central nervous system (CNS) poses a unique challenge for drug delivery. The blood–
brain barrier significantly hinders the passage of systemically delivered therapeutics and the …